Laura J. Esserman, MD, professor, Departments of Surgery and Radiology, affiliate faculty, Institute for Health Policy Studies, University of California, San Francisco, director, Carol Franc Buck Breast Care Center; co-leader, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the I-SPY 2 trial, a clinical trial for women with newly diagnosed, locally advanced breast cancer.

Esserman says the mechanism of the trial is very successful. Pharmaceutical companies, diagnostic companies, academic institutions, and professionals worked together to evaluate drugs by class.

The first drug to be evaluated was veliparib, a PARP inhibitor, which was used in combination with carboplatin. Esserman says the combination showed benefit in patients with triple-negative disease. The results of this phase II trial led physicians to believe that a phase III study of veliparib plus carboplatin will be a successful trial.

Videos

Laura J. Esserman, MD, discusses the I-SPY 2 trial, a clinical trial for women with newly diagnosed, locally advanced breast cancer.

Laura J. Esserman, MD

Articles

Dr. Esserman Discusses the I-SPY 2 Trial